Tuesday 28th March 2023
Last week, the scope for a new revision of the British Society for Rheumatology’s systemic sclerosis (SSc) guideline was published in the ‘Rheumatology: Advances in Practice’ journal. SRUK are excited to be playing a role in this timely and relevant project. Read on to find out more about the BSR guideline and how it’s revision could benefit you!
Friday 10th March 2023
Calcinosis is often a debilitating and painful symptom of systemic sclerosis. Last winter, SRUK led a piece of research in partnership with Professor Ariane Herrick, which aimed to build our understanding of the effect of calcinosis on people with scleroderma. We are thrilled to announce that the findings, which our community contributed to, have been published in the journal ‘Rheumatology.’ Read on to find out more about what we learned!
Friday 25th March 2022
On the 17th March 2022 the UK’s Medicine and Health products Regulation Agency (MHRA) approved a new drug, Evusheld, for the prevention of COVID-19 infection.
Thursday 10th March 2022
Can you imagine a future where we will be able to eliminate trial and error in prescribing medications by predicting the best treatment for a person’s scleroderma before they even receive it! The winning proposal of the SRUK/ WSF Stratified Medicine of the Future Award aspires to make this a reality.
Friday 19th March 2021
Clinical trials are the only way to ensure that new treatments are effective. But how exactly does the process work? FInd out why 'outcome measures’ and ‘endpoints’ are crucial, and how SRUK funding is playing a key role in improving the measures used in treatments for scleroderma.
Thursday 5th March 2020
Advice from Public Health England on COVID-19 to help you understand the implications if you have scleroderma and Raynaud's.
Friday 22nd March 2019
Dr. Elizabeth Renzoni has been working as a consultant respiratory physician at Royal Brompton Hospital in the ILD Unit and an honorary senior lecturer at Imperial College London since 2006. We spoke to her about her career in research.
Wednesday 20th March 2019
Iloprost is used to treat a range of conditions, such as scleroderma, Raynaud's phenomenon, pulmonary hypertension and other diseases where blood vessels are constricted. By relaxing the blood vessels, it makes it easier for blood to flow through, helping to limit the symptoms.
Thursday 14th March 2019
SRUK recently funded David and his team to investigate factors that contribute to the development of calcinosis in scleroderma patients. Find out more about him in our new Meet the Scientist series.
Tuesday 12th March 2019
Here is a little insight into the lives of some of the researchers we fund, what keeps them in the laboratory and the future of research.
